The Effect of Low-level Laser Therapy on Levels of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor 1 in Gingival Crevicular Fluid of Stage 3-4, Grade C Periodontitis Patients Received Non-surgical Periodontal Treatment.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Periodontal Diseases
- Sponsor
- University of Beykent
- Enrollment
- 15
- Locations
- 1
- Primary Endpoint
- the change in GCF tissue plasminogen activator
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The present study aimed to investigate the effects of low-level laser therapy (LLLT) as an adjunct to non-surgical periodontal treatment (NSPT) on the plasminogen-activating system in Stage 3-4, Grade C periodontitis patients.
Detailed Description
Limited data is available regarding the effects of various periodontal treatment protocols on GCF t-PA and PAI-1 levels, and the extent to which LLLT in conjunction with NSPT affects these levels in patients with Stage 3-4, Grade C periodontitis is unknown. Therefore, this study measured standard clinical outcomes and GCF t-PA and PAI-1 levels in patients with Stage 3-4 Grade, C periodontitis in order to assess the use of LLLT as an adjunct to standard NSPT. This split-mouth study was conducted with 15 Stage 3-4, Grade C periodontitis patients and 15 healthy individuals matched for age and sex. Participants were grouped as follows: Periodontitis/NSPT (Sham); Periodontitis/NSPT+LLLT (LLLT); Periodontally Healthy (Control). LLLT was applied following NSPT and again on post-treatment Days 2 and 7. Clinical parameters were recorded at baseline (i.e. before NSPT) and on Day 30. Gingival crevicular fluid (GCF) samples were collected at baseline and during follow-up visits on Days 7, 14 and 30. GCF t-PA and PAI-1 levels were measured with ELISA.
Investigators
Ferda Pamuk Özer
Associate professor
University of Beykent
Eligibility Criteria
Inclusion Criteria
- •Stage 3-4, Grade C periodontitis (at least one site with probing depth (PD) and clinical attachment level (CAL) ≥5 mm in their incisors and/or first molars and at least 6 other teeth with similar PD and CAL measurements, with alveolar bone loss confirmed by radiography; familial aggregation;
- •presence of ≥16 teeth;
- •no periodontal treatment in the 6 months prior to data collection;
- •non-smoker
Exclusion Criteria
- •systemic problems, including a medical history of cancer, rheumatoid arthritis, diabetes mellitus, or cardiovascular disease;
- •compromised immune system;
- •pregnancy, menopause, or lactation;
- •ongoing drug therapy that might affect the clinical characteristics of periodontitis;
- •use of systemic antimicrobials during the 6 weeks prior to data collection
Outcomes
Primary Outcomes
the change in GCF tissue plasminogen activator
Time Frame: baseline and during follow-up visits on Days 7, 14 and 30.
Gingival crevicular fluid (GCF) samples were collected before SRP treatment and on days 7, 14 and 30 of follow- up and the change of the related mediator at those time points. The Amount of the related mediator were evaluated using enzyme- linked immunosorbent assay \[ELISA\] kit. Total amounts (pg/30 s) of the mediator collected from each sample in a 30- second period were calculated and recorded for analysis.
the change in GCF plasminogen activator inhibitor 1
Time Frame: baseline and during follow-up visits on Days 7, 14 and 30.
Gingival crevicular fluid (GCF) samples were collected before SRP treatment and on days 7, 14 and 30 of follow- up and the change of the related mediator at those time points. The Amount of the related mediator were evaluated using enzyme- linked immunosorbent assay \[ELISA\] kit. Total amounts (pg/30 s) of the mediator collected from each sample in a 30- second period were calculated and recorded for analysis.